Business Context and Reporting Period
This Form 8-K was filed by Unum Therapeutics Inc. (noting a discrepancy with the request metadata which listed "Cogent Biosciences, Inc.") on June 21, 2019. The registrant is a Delaware corporation with its principal executive offices in Cambridge, Massachusetts, and its common stock trades on The Nasdaq Global Select Market under the symbol UMRX. The company is classified as an emerging growth company.
Key Financial Metrics
This filing is a current report regarding a material definitive agreement and does not contain financial statements, revenue, profit, cash flow, margin, or debt balance data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The primary material change reported is the entry into a Third Amendment to the Loan Security Agreement with Pacific Western Bank, originally dated January 19, 2017. The key provision of this amendment is the extension of the loan draw deadline from its previous date to June 30, 2020.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies are detailed in the body of this report, other than the standard reference to the full text of the amendment for complete terms.
Investor Verification Checklist
- Verify the correct registrant name (Unum Therapeutics Inc. vs. Cogent Biosciences, Inc.) to ensure data relevance.
- Review Exhibit 10.1 (Third Amendment to Loan and Security Agreement) for specific terms, interest rates, covenants, and conditions attached to the extended draw deadline.
- Confirm the company's current cash position and liquidity status in the most recent 10-Q or 10-K to assess the necessity of the extended draw deadline.
- Check for any subsequent filings regarding the utilization of the loan facility or further amendments.